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Abstract
Background: The emergence of extended-spectrum beta-lactamase (ESBL)-producing isolates has important clinical
and therapeutic implications. High prevalence of ESBL-producing Enterobacteriaceae has been reported in the
literature for clinical samples from a variety of infection sites. The present study was undertaken to evaluate the
prevalence of ESBL-producing Enterobacteriaceae, and to perform molecular characterization and antimicrobial
susceptibility testing of clinical isolates from patients admitted to the intensive care units at Hamad Medical
Corporation, Doha, Qatar, from November 2012 to October 2013.
Methods: A total of 629 Enterobacteriaceae isolates were included in the study. Identification and susceptibility
testing was performed using Phoenix (Becton Dickinson) and the ESBL producers were confirmed by double-disk
potentiation as recommended by the Clinical and Laboratory Standards Institute. Molecular analysis of the ESBL
producers was performed by polymerase chain reaction.
Results: In total, 109 isolates (17.3 %) were confirmed as ESBL producers and all were sensitive to meropenem in
routine susceptibility assays. Most of the ESBL producers (99.1 %) were resistant to amoxicillin/clavulanic acid and
ceftriaxone and 93.6 % were resistant to cefepime. Among the ESBL-producing genes, blaCTX-M (66.1 %) was the
most prevalent, followed by blaSHV (53.2 %) and blaTEM (40.4 %).
Conclusions: These findings show the high prevalence of ESBL-producing Enterobacteriaceae within the intensive
care units at Hamad Medical Corporation, Qatar, and emphasize the need for judicious use of antibiotics and the
implementation of strict infection control measures.
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Background
The emergence of extended-spectrum beta-lactamase
(ESBL)-producing Enterobacteriaceae, particularly Escher-
ichia coli and Klebsiella pneumoniae, presents a significant
threat to human health and these organisms are now
listed among the six drug-resistant pathogens for which
there are few potentially effective drugs [1]. The first case
of ESBL was reported in the 1980s in Europe and subse-
quently in the United States, soon after the introduction
of third-generation cephalosporins [2]. Over the last two
decades, there has been an exponential increase world-
wide in β-lactamase production and the prevalence of
ESBL-producing Enterobacteriaceae, contributing to a
significant increase in antimicrobial resistance [3–5]. Im-
portantly, infections with ESBL-producing pathogens are
associated with poor clinical outcomes, longer hospital
stays, higher mortality rates, and greater hospital expenses
[6, 7]. In addition, there has been a rapid and widespread
dissemination of ESBL-producing Enterobacteriaceae in
communities as well as in hospital-associated infections,
resulting in a worldwide health crisis [8].
The ESBL genes are predominantly plasmid encoded
[9] and most belong to the class A β-lactamases, which
can be divided into three genotypes: TEM, SHV, and
CTX-M [6]. During the 1990s, ESBL-producing Entero-
bacteriaceae, E. coli and K. pneumonia, were described
mainly as members of the TEM- and SHV-β-lactamase
families [10]. Later in 2000, K. pneumoniae was reported
as the major ESBL producer with TEM and SHV as the
predominant genotypes [3]. However, ESBL-producing
E. coli of the CTX-M genotype is now more prevalent
in Western and Asian countries [3]. The CTX-M β-
lactamases comprise more than 50 different types,
which can be divided into five groups based on their
amino acid identities: CTX-M-1, CTX-M-2, CTX-M-8,
CTX-M-9, and CTX-M-25 [11, 12].
Several reports have described the prevalence of ESBLs
in the Middle East North Africa (MENA) region and most
of the Gulf Cooperation Countries [13]. However, there is
insufficient scientific data on the epidemiology of ESBLs
available from the State of Qatar. To the best of our know-
ledge, this is the first study on the molecular epidemiology
and antimicrobial susceptibilities of ESBL-producing En-
terobacteriaceae from patients in the State of Qatar.
Methods
Study design
The present prospective study was conducted on routine
specimens received at the Microbiology Laboratory of
the Department of Laboratory Medicine and Pathology,
Hamad Medical Corporation (HMC), from patients
admitted to the intensive care units (ICUs) at HMC.
This study was approved (Protocol no. RC/75813/2013)
by the Institutional Review Board of HMC.
Clinical isolates/strains
A total of 629 Enterobacteriaceae isolates (a single iso-
late per patient) were collected between November 2012
and October 2013 from various clinical specimens as
part of routine clinical care. These clinical isolates were
preserved at −70 °C for further analysis. For each
individual, age, nationality, and clinical history were col-
lected from patients’ medical records. Infections occur-
ring more than 48 h after admission were considered
hospital acquired [14].
The standard strains of E. coli (ATCC 25922) and
K. pneumoniae (ATCC 700603) were used for identifica-
tion and antimicrobial drug susceptibility testing and K.
pneumoniae (NCTC 13368), E. coli (NCTC 13351), and E.
coli NCTC (13353) were used as positive controls for
blaSHV, blaTEM, and blaCTX-M in polymerase chain reac-
tion (PCR) assays, respectively.
Identification and antimicrobial drug susceptibility testing
The identification and antimicrobial susceptibility test was
performed with Phoenix using the NMIC/ID-5 panel ac-
cording to the manufacturer’s recommendations (BD Bio-
sciences, Heidelberg, Germany). All samples, which tested
positive for ESBL by Phoenix or showed an MIC of >2 μg/
mL for ceftazidime, aztreonam, and ceftriaxone, were con-
sequently confirmed by a double-disk potentiation test with
ceftazidime, amoxicillin/clavulanic acid, ceftriaxone, and
cefoxitin antibiotics and interpretation was carried out as
previously described [15, 16]. Briefly, a microbial suspen-
sion with 0.5 McFarland turbidity was inoculated onto
Mueller–Hinton agar (Oxoid Ltd., Basingstoke, Hampshire,
England), followed by overnight incubation at 37 °C, and
susceptibility/resistance patterns were determined.
DNA extraction and detection of ESBL genes by PCR
Bacterial DNA was extracted using the boiling lysis
method [17]. Briefly, a few colonies were suspended in
Tris-EDTA buffer (pH 8.0). The suspensions were boiled
at 100 °C for 10 min and subsequently centrifuged at
15871 g for 5 min. The supernatant was transferred to
new tubes and stored at −20 °C for subsequent PCR
analysis. PCR reactions were carried out using the
following protocol: 2 μL of extracted DNA was com-
bined with 12.5 μL of 2X master mix, 1 μL forward and
1 μL reverse primer, and the mixture was made up to a
25 μL volume with nuclease-free water. PCR ampli-
fication (Veriti 96 Well Thermal Cycler-Applied Biosys-
tems, Pittsburg, PA, USA) was initiated at 96 °C for 1
min, followed by 35 cycles at 96 °C for 1 min, annealing
(55 °C for TEM, and 50 °C for SHV and CTX-M-1) for 1
min, and extension at 72 °C for 2 min. Final extension
was at 72 °C for 10 min. All samples were analyzed in
duplicate. A positive control (plasmid carrying cloned
ESBL gene fragment) and a negative control (nuclease-
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free water) were included in each amplification reaction.
After the last cycle, the products were stored at 4 °C for
further analysis. The PCR products (1/10 volume) were
analyzed by gel electrophoresis (Bio-Rad,
Hercules, CA, USA) using 2 % agarose gels in 1X TAE
buffer (Tris-acetate EDTA). The gels were stained with
ethidium bromide (Sigma, St. Louis, MO, USA), and the
PCR products were visualized under ultraviolet light. A
single band with an amplicon size of 1,150 bp was
observed for TEM, 885 bp for SHV, and 499 bp for the
CTX-M-1 group (Table 1) [18].
Results
Demographic characteristics of the study population
Samples were collected from patients with suspected
bacterial infection from different ICUs (29.4 % from
Medical, 28.5 % Surgical, 16.5 % Trauma, 15.6 %
Pediatric, and 10 % from Neonatal) attached to HMC
hospitals. Samples were subjected to culturing and sub-
sequent pathogen identification. The demographic pro-
file of the studied population is summarized in Table 2
and shows that 59.6 % (n = 65) of samples were col-
lected from male patients and 40.4 % (n = 44) of samples
were from female patients. Samples were collected from
patients ranging in age from 1 month to 86 years, with a
mean age of 40.31 years (SD = 26.79). It is noteworthy
that 68.8 % of patients were non-Qatari and 86.2 % were
admitted to hospital for >2 days.
Distribution of clinical isolates
During the study period, a total of 109 (17.3 %)
ESBL-producing Enterobacteriaceae were isolated.
Amongst the isolates, K. pneumoniae (51.4 %, n = 56)
was the most common ESBL-producing organism,
followed by E. coli (34.7 %, n = 38), and the numbers
of organisms other than E. coli and K. pneumoniae
were low (13.8 %, n = 15) (Fig. 1). These pathogens
were isolated from a variety of clinical samples, re-
spiratory 35.8 % (n = 39), blood 27.5 % (n = 30),
urine 24.8 % (n = 27), fluids 6.4 % (n = 7), and
others 5.5 % (n = 6) (Fig. 1).
Antimicrobial resistance/susceptibility profile of ESBL
isolates
Antibiotic resistance/susceptibility patterns of ESBL-
producing pathogens are shown in Fig. 2. Among the
carbapenems, all ESBL-producing isolates showed 100 %
susceptibility to meropenem and slightly reduced sus-
ceptibility to imipenem (99.1 %) and ertapenem (97.2 %).
Among the β-lactam/β-lactamase inhibitor combina-
tions, 78 % were sensitive to piperacillin/tazobactam,
whereas 99.1 % were resistant to amoxicillin/clavulanic
acid. Susceptibilities to cephalosporins were found to be
very low (ceftriaxone 0.9 % and cefepime 6.4 %). The
clinical isolates showed high sensitivity to amikacin
(97.2 %) compared with gentamicin (67 %) amongst
the aminoglycosides. The susceptibility to other clas-
ses of antimicrobials such as tigecycline, ciprofloxacin,
and trimethoprim/sulfamethoxazole was relatively low
(64.2 %, 60.6 %, and 38.5 % respectively).
Molecular genotyping of ESBL-producing isolates
The ESBL-producing pathogens confirmed by pheno-
typic methods were also molecularly analyzed. Of the
109 ESBL isolates, 24.7 % harbored multiple bla genes
simultaneously and the prevalence of blaCTX-M was
highest at 66.1 %, followed by blaSHV at 53.2 %,
and blaTEM at 40.4 % (Fig. 3). The majority of the
CTX-M-1-positive isolates were E. coli (76.3 %) and
K. pneumoniae (75 %); however, all TEM and SHV-
positive isolates were K. pneumoniae (53.6 % and 87.5 %
respectively). Furthermore, all three bla genes (TEM,
SHV, and CTX-M-1) were detected in 46.4 % of K.
pneumoniae isolates, while two genes (SHV/CTX-M-1)
were present in 17.8 % of K. pneumoniae and 2.6 % of E.
coli isolates, with TEM/CTX-M-1 being present in
18.4 % of E. coli and 7.1 % of K. pneumoniae and
Table 1 Primers used for polymerase chain reaction amplification of extended-spectrum beta-lactamase genes (TEM, SHV and CTX-M-1)
Gene Primer Sequence (5′3′) Amplicon size (bp)
TEM TEM-FTEM-R TTCTTGAAGACGAAAGGGCACGCTCAGTGGAACGAAAAC 1,150
SHV SHV-FSHV-R CACTCAAGGATGTATTGTGTTAGCGTTGCCAGTGCTCG 885
CTX-M-1 group CTXM1-FCTXM1-R GACGATGTCACTGGCTGAGCAGCCGCCGACGCTAATACA 499
Table 2 Demographic profile of the study population infected
with extended-spectrum beta-lactamase-producing pathogens
in the State of Qatar
Total Nationality Hospital stay
Gender ↓ No. (%) Qatari non-Qatari <2 days >2 days
Male 65 (59.6) 19 46 6 59
Female 44 (40.4) 15 29 9 35
Total No. (%) 109 34 (31.2) 75 (68.8) 15 (13.8) 94 (86.2)
Age groups (Years) ↓
<1 18 (16.5) 5 13 4 14
1-12 8 (7.4) 4 4 2 6
13-30 13 (11.9) 2 11 0 13
31 -50 24 (22) 3 21 3 21
>50 46 (42.2) 20 26 6 40
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TEM/SHV being detected in only 5.3 % of E. coli iso-
lates (Fig. 3). None of the bla genes were detected in
Serratia marcescens, Citrobacter braakii, Citrobacter
freundii, Klebsiella oxytoca, or Proteus penneri (data
not shown).
Discussion
In this study, we examined the prevalence of ESBL-
producing Enterobacteriaceae and carried out molecular
characterization and antimicrobial susceptibility testing
of clinical samples from patients admitted to ICUs at
HMC, Doha, Qatar. A total of 629 Enterobacteriaceae
isolates were evaluated for the production of ESBL en-
zymes. In our study, the major ESBL producer was found
to be K. pneumoniae followed by E. coli and other species,
which is in agreement with previous studies [13, 19], but
overall the prevalence of ESBL-producing pathogens was
substantially lower (17.3 %) than that reported by other
studies from neighboring MENA and Asian countries [13,
20–26]. Methodological differences may explain the differ-
ences observed in the measured prevalence levels.
In the present study, the respiratory tract was the
major source of ESBL-producing isolates, followed by
the blood and other sampling sites. Similar findings have
been reported for the ICUs of tertiary care hospitals in
Mexico and India, where the major source of ESBL-
producing isolates were the respiratory tract and blood,
respectively [27, 28]. However, in the Gulf Cooperation
Countries region, urine and blood were reported as the
major source of ESBL-producing bacteria [13, 26, 29].
The highest level of resistance, in the current study,
was observed to be amoxicillin/clavulanic acid, ceftriax-
one, and cefepime, while all isolates were susceptible to
meropenem, with decreasing levels of susceptibility to
imipenem, ertapenem, amikacin, piperacillin/tazobactam,
gentamicin, tigecycline, ciprofloxacin, and trimethoprim/
sulfamethoxazole. Recently, Somily et al. [30] reported
similar susceptibility rates among E. coli and K. pneumo-
niae isolates from a tertiary care hospital at Riyadh,
Kingdom of Saudi Arabia. However, susceptibility to
Fig. 1 Distribution of extended-spectrum beta-lactamase-producing organisms among Enterobacteriaceae isolates and the site of isolation.
# Enterobacter cloacae, Citrobacter amalonaticus, Enterobacter aerogenes, Citrobacter amalonaticus, Serratia marcescens, Citrobacter braakii,
Citrobacter freundii, Klebsiella oxytoca, Proteus penneri
Fig. 2 In vitro activity of the identification and antimicrobial
susceptibility test panel of antimicrobial agents against clinical
extended-spectrum beta-lactamase-producing isolates. The in
vitro activity of antimicrobial agents against clinical isolates was
analyzed by BD Phoenix. AK (amikacin), AMC (amoxicillin/
clavulanic acid), PM (cefepime), FX (cefoxitin), CRO (ceftriaxone),
CI (ciprofloxacin), ETR (ertapenem), GM (gentamicin), IP (imipenem),
MP (meropenem), PTC (piperacillin/tazobactam), TGC (tigecycline),
TS (trimethoprim/sulfamethoxazole)
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piperacillin/tazobactam and ciprofloxacin were lower in
our study compared with isolates from a hospital at
Dammam, Kingdom of Saudi Arabia [26]. Furthermore,
in Sudan, ESBL-producing E. coli were highly resistant
to trimethoprim/sulfamethoxazole and ciprofloxacin but
less resistant to amoxicillin/clavulanic acid compared
with the present study, but similar susceptibility rates
were observed to amikacin and gentamicin [29]. The
resistance observed with ertapenem and imipenem
compared with merepenem could possibly result from
carbapenemase production and/or resistance owing to
the loss of porins and/or hyper-production of AmpC;
however, this was not further evaluated because of the
limitations of the present study.
The predominant genotype of ESBL-producing E. coli
and K. pneumonia has changed from TEM and/or SHV to
CTX-M-1 [3], and currently, CTX-M has been reported
to be the most prevalent genotype among ESBL-
producing isolates [13, 26, 28, 31–33]. In this study, mo-
lecular genotyping of ESBL-positive isolates showed that
the CTX-M-1 gene was the most common among E. coli
and K. pneumonia followed by SHV and TEM, which was
consistent with previous reports from Turkey and India
[34, 35]. Additionally, our results showed that only 24.7 %
of isolates produced all three genes concurrently and 10.1
% of isolates co-produced TEM/CTX-M-1 and SHV/
CTX-M-1. These findings obscure the detection rates,
affect subsequent treatment strategies, and could be the
reason for resistance to β-lactamase inhibitors [26].
Conclusions
Compared with other countries in the MENA region,
our study shows relatively low prevalence (17.3 %) of
ESBL-producing Enterobacteriaceae. Though lower
than in other countries and regions, our study suggests
that there is sufficient infection burden to warrant
public health interventions. Notably, the majority of
isolates were multi-drug resistant and belonged to
plasmid-type CTX-M. The emergence of CTX-M-
producing Enterobacteriaceae isolates is of major con-
cern and highlights the need for further surveillance in
this area. As meropenem shows good activity against
these ESBL producers, it should be restricted for man-
aging patients with suspected Gram-negative bacterial
infections with ESBL production. Additionally, anti-
microbial stewardship and early detection by active
surveillance coupled with an effective infection control
program are key to reducing or halting the spread of
ESBL producers in hospitals and communities in the
State of Qatar.
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